← All trials
NCT01652014
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2014
- Primary completion
- Jan 1, 2017
- Completion date
- Jan 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of Medicine and Dentistry of New JerseyLead sponsor
- Rutgers UniversityOverall official - principal investigator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
- Burkitt Lymphoma
- Hodgkin Disease
- Leukemia, Hairy Cell
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Lymphomatoid Granulomatosis
- Waldenstrom Macroglobulinemia
- Multiple Myeloma
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Sezary Syndrome
- Testicular Neoplasms
- Transplantation
- Leukemia, Lymphocytic, Chronic, B-Cell
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia-Lymphoma, Adult T-Cell
- Leukemia, Myeloid, Chronic-Phase
- Leukemia, Myeloid, Acute
- Lymphoma, T-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Leukemia, Large Granular Lymphocytic
- Intraocular Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.